01
May
An innovation-driven global pharmaceutical company Glenmark Pharmaceuticals Limited has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin with Pioglitazone. This is the only available brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name ZitaPlusPio which contains Teneligliptin (20 mg) + Pioglitazone (15 mg) to be taken once a day. Glenmark is the first company in India to market the innovative FDC of Teneligliptin+ Pioglitazone which is approved by the Drug Controller General of India. It will be useful for patients who…